


WELCOME

Clozapine & LAI Virtual Forum

December 7, 2022 | 4:00 – 4:45 pm ET

The Clozapine & LAI Virtual Forum is an all-new, peer-to-peer, interactive dialogue between psychiatrists, nurse practitioners, and other prescribing clinicians.

It is informal, no registration required — just join our Zoom call and share your challenges and questions on the month's trending topic around either clozapine or LAIs.



TODAY'S TOPIC:

**Pharmacist Administration of Long-Acting Injectable
(LAI) Antipsychotics**



MODERATORS

Robert Cotes, MD

SMI Adviser Physician Expert; Emory University

Dr. Robert Cotes, MD, is an Associate Professor at Emory University School of Medicine in the Department of Psychiatry and Behavioral Sciences. He has interest in clozapine, characterizing persistent symptoms of schizophrenia, understanding cardiometabolic side effects of antipsychotic medications, and first episode psychosis.

Donna Rolin, PhD, APRN

SMI Adviser Nursing Expert; University of Texas, Austin

Dr. Donna Rolin is Clinical Associate Professor and the Director of the Psychiatric Mental Health Nurse Practitioner program at the University of Texas with 23 years of experience in psychiatric nursing, including inpatient, community, forensic, and older adult settings.

Megan Ehret, PharmD, MS, BCPP


SMI Adviser Pharmacy Consultant, University of Maryland

Dr. Megan Ehret is a Professor at University of Maryland School of Pharmacy in the Department of Pharmacy Practice and Science. She is a Past-President of the College of Psychiatric and Neurologic Pharmacists. Her current interests include psychotropic medication adherence and the incorporation of the psychiatric pharmacist in practice.

Discussion Questions for Virtual Forum: Pharmacist Administration of Long-Acting Injectable (LAI) Antipsychotics

- What does the administration of LAI antipsychotics look like in your practice setting?
- How do patients receiving telehealth receive LAI antipsychotics?
 - Do they come to the clinic for injections?
 - Do they utilize a pharmacy or traveling nurse service?
- What is your clinic's back up plan if the administration staff is out of the clinic?
 - Do injections get rescheduled?
 - Does another person administer medications?

Pharmacist Authority to Administer Long-Acting Antipsychotics



“Certain Drugs/Situations”

- **Florida**
 - Long-acting antipsychotic medication (need both physician protocol and patient-specific prescription)
- **Illinois**
 - In the context of patient education on the proper use or delivery of medications
 - Long-acting or extended-release form opioid antagonists for the treatment of substance use disorder (after initial admin)
 - Alpha-hydroxyprogesterone caproate
 - Long-term antipsychotic medications
- **Maryland**
 - “Maintenance injectable medication”: injection (other than IV) that treats a chronic need, condition, or disorder; includes medications for the treatment of a psychiatric disorder or substance use disorder, contraception, and vitamins
 - Self-administered drugs and maintenance injectable medications that are not biologics
- **Kansas**
 - Self-administered drugs

“Certain Drugs/Situations”

- **Minnesota**

- First dosage and medical emergencies
- Intramuscular and subcutaneous administration used for the treatment of alcohol or opioid dependence
- Intramuscular and subcutaneous administration used to treat mental illnesses

- **North Carolina**

- Long-acting injectable medications, including testosterone injections and vitamin B12, to persons at least 18 years of age
- Any prescribed, self-administered injectable medication
- “Immunizing pharmacists”

- **Ohio**

- An addiction treatment drug administered in a long-acting or extended-release form
- An antipsychotic drug administered in a long-acting or extended-release form
- Hydroxyprogesterone caproate or Medroxyprogesterone acetate
- Cobalamin
- Physician protocol needed

Collaborative Practice Agreements/Physician Protocol

- Formal practice agreement between a pharmacist and prescriber
- Defines the functions given to the pharmacist by the collaborating prescriber
- Challenges:
 - Potential need for agreement with each individual pharmacist versus a pharmacy
 - Cost to create the agreement
 - Paperwork associated with the agreement

SMI Adviser LAI Center of Excellence

- Clinical Tips
- Educational Webinars
- VF Recordings
- <https://smiadvise.org/about/lai>



Welcome to the Long-Acting Injectable (LAI) Center of Excellence (COE)

SMI Adviser created the LAI COE to promote the safe and effective use of LAIs. The ultimate goal of this effort is to improve the lives of individuals who have schizophrenia, schizoaffective, and bipolar disorders. The LAI COE provides clinicians with training opportunities, technical assistance, and vetted resources. These include:

- Live and on-demand webinars
- Virtual Learning Collaboratives
- Virtual Forums
- Email listserv
- On-demand consultations
- Intensive consultation to sites or communities
- Clinical tips and resources

The LAI COE is led by SMI Nursing Expert, Donna Rolin, PhD, APRN, SMI Adviser Physician Expert, Robert Cotes, MD, and SMI Adviser content partner, National Association of State Mental Health Program Directors (NASMHPD), and supported by members of the LAI Workgroup.

For individual and family resources on using long-acting injectables, visit the individual and family [Knowledge Base](#).

FEEDBACK

Please help us improve the Clozapine & LAI Virtual Forum by completing this survey:
<http://smiadviser.org/forumfeedback>



Pre-submit Cases

www.smiadviser.org/vfcases

UPCOMING VIRTUAL FORUM

Obsessive Compulsive Symptoms
and Psychosis on Clozapine

1/11/23 @4 – 4:45 PM ET

For additional questions and resources – join the Clozapine and LAI Centers of Excellence Exchange Community

- www.smiadviser.org/cloz_lai_signup

An APA and SAMHSA Initiative

